Bactiguard Holding AB announced its interim results for the second quarter of 2025, demonstrating a continued positive EBITDA momentum. The company's EBITDA for the quarter was SEK 4 million, an increase from SEK 1.2 million in Q2 2024. Despite this, total revenue for the quarter decreased by 14.4% to SEK 52.1 million compared to SEK 60.9 million in Q2 2024. Net sales also saw a reduction, amounting to SEK 2 million, a decrease of 15.9%. The operating loss for the quarter was SEK 7.3 million, an improvement from the SEK 10.8 million loss in the same period last year. The net loss narrowed to SEK 8.1 million from SEK 14.3 million in Q2 2024, with a loss per share of SEK 0.24 compared to SEK 0.41 previously. License revenues totaled SEK 34.1 million, down from SEK 37.8 million in the previous year, with BD license partner revenues impacted by longer timelines for market registration, resulting in a decrease to SEK 19.2 million. Zimmer Biomet's revenues, however, increased to SEK 14.2 million due to minimum royalties. The Wound Management portfolio reported revenues of SEK 13.8 million, slightly down from SEK 14.7 million in Q2 2024. Cash flow from operating activities for the quarter was SEK 1.7 million, translating to SEK 0.05 per share.